نتائج البحث - "Davide Melisi"

1

Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

المؤلفون: Alessandro Cavaliere, Michaela Deiana, Camilla Zecchetto, Davide Melisi, Raffaela Santoro, Sara Lonardi, Geny Piro, Domenico Mangiameli, Vita Fedele, Diana Bazan, Francesca Simionato, Valeria Merz, Maria Teresa Valenti, Fabio Sabbadini

المصدر: Clinical Cancer Research. 26:4661-4669

مصطلحات موضوعية: Adult, Male, Transcriptional Activation, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, TAK1, Irinotecan, Deoxycytidine, Small hairpin RNA, Mice, 03 medical and health sciences, 0302 clinical medicine, In vivo, Cell Line, Tumor, Pancreatic cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Animals, Humans, In patient, Prospective Studies, Interleukin 8, Response Evaluation Criteria in Solid Tumors, Aged, Aged, 80 and over, business.industry, Interleukin-8, Middle Aged, MAP Kinase Kinase Kinases, medicine.disease, Xenograft Model Antitumor Assays, Gemcitabine, Gene Expression Regulation, Neoplastic, Pancreatic Neoplasms, 030104 developmental biology, Drug Resistance, Neoplasm, Gene Knockdown Techniques, 030220 oncology & carcinogenesis, Cohort, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d460b791de2a3069098a593c52de7ef7Test
https://doi.org/10.1158/1078-0432.ccr-20-0395Test

2

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

المؤلفون: Yumin Zhao, Teresa Macarulla, Karim A. Benhadji, Rocio Garcia-Carbonero, M. Lanasa, Davide Melisi, Do Youn Oh, Shawn T. Estrem, Michael Man, Antoine Hollebecque, Emiliano Calvo, Leena Gandhi, Susan C. Guba, Anna M. Varghese, Erkut Borazanci, Valeria Merz, Camilla Zecchetto, Emin Avsar, Ivelina Gueorguieva

المساهمون: Institut Català de la Salut, [Melisi D] Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Università degli Studi di Verona, Verona, Italy. [Oh DY] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. [Hollebecque A] Institut Gustave Roussy, Villejuif, France. [Calvo E] START Madrid–CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Varghese A] Memorial Sloan Kettering Cancer Center, New York, New York, USA. [Borazanci E] HonorHealth Research Institute, Scottsdale, Arizona, USA. TGen, Phoenix, Arizona, USA. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Durvalumab, Time Factors, medicine.medical_treatment, Receptor, Transforming Growth Factor-beta Type I, B7-H1 Antigen, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, Other subheadings::/therapeutic use [Other subheadings], Neoplasm Metastasis, Immune Checkpoint Inhibitors, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], RC254-282, Clinical/Translational Cancer Immunotherapy, Aged, 80 and over, biology, clinical trials as topic, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antibodies, Monoclonal, Middle Aged, Progression-Free Survival, Europe, 030220 oncology & carcinogenesis, Disease Progression, Quinolines, Molecular Medicine, Female, immunotherapy, Antibody, Signal Transduction, Adult, medicine.medical_specialty, Combination therapy, Immunology, therapies, investigational, 03 medical and health sciences, Refractory, Pharmacokinetics, Internal medicine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Republic of Korea, Pàncrees - Càncer - Tractament, medicine, Galunisertib, tumor microenvironment, Humans, Protein Kinase Inhibitors, Aged, Pharmacology, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Immunotherapy, medicine.disease, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], United States, Pancreatic Neoplasms, 030104 developmental biology, tumor biomarkers, biology.protein, Avaluació de resultats (Assistència sanitària), Pyrazoles, business, Progressive disease